for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hologic, Inc.

HOLX.O

Latest Trade

72.53USD

Change

0.87(+1.21%)

Volume

70,014

Today's Range

71.85

 - 

72.56

52 Week Range

60.10

 - 

85.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
71.66
Open
71.85
Volume
70,014
3M AVG Volume
30.92
Today's High
72.56
Today's Low
71.85
52 Week High
85.00
52 Week Low
60.10
Shares Out (MIL)
256.23
Market Cap (MIL)
18,164.91
Forward P/E
9.30
Dividend (Yield %)
--

Next Event

Q4 2021 Hologic Inc Earnings Release

Latest Developments

More

Hologic Inc Says Refinanced Its Term Loan And Revolving Credit Facility By Entering Into Refinancing Amendment No. 2

Hologic Announces Q3 Revenue $1.168 bln

Hologic Obtains European CE Mark For Use Of Saliva Samples With COVID-19 Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hologic, Inc.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a range of diagnostics products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a portfolio of solutions for breast cancer care for radiology, pathology and surgery. The GYN Surgical segment offers a range of products, including its NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System as well as its Fluent Fluid Management system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm.

Industry

Medical Equipment & Supplies

Contact Info

250 Campus Dr

MARLBOROUGH, MA

01752-3020

United States

+1.508.2632900

https://www.hologic.com/

Executive Leadership

Stephen P. Macmillan

Chairman of the Board, President, Chief Executive Officer

Karleen Marie Oberton

Chief Financial Officer

Kevin R. Thornal

Division President - Diagnostics

Allison P. Bebo

Senior Vice President - Human Resources

John M. Griffin

General Counsel

Key Stats

1.75 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.2K

2019

3.4K

2020

3.8K

2021(E)

5.3K
EPS (USD)

2018

2.230

2019

2.430

2020

3.980

2021(E)

7.786
Price To Earnings (TTM)
9.19
Price To Sales (TTM)
3.21
Price To Book (MRQ)
4.68
Price To Cash Flow (TTM)
7.51
Total Debt To Equity (MRQ)
81.02
LT Debt To Equity (MRQ)
69.06
Return on Investment (TTM)
32.35
Return on Equity (TTM)
26.43

Latest News

Latest News

Supreme Court signals possible limits to patent law's assignor estoppel

The U.S. Supreme Court appeared open to the possibility of limiting the patent law doctrine of assignor estoppel during oral arguments Wednesday in a patent dispute between medical device makers Minerva Surgical Inc and Hologic Inc.

BRIEF-Hologic Launches Its First Cart-Based Ultrasound System, Supersonic Mach 40

* HOLOGIC LAUNCHES ITS FIRST CART-BASED ULTRASOUND SYSTEM, SUPERSONIC™ MACH 40 Source text for Eikon: Further company coverage:

BRIEF-Grifols Collaborates With Hologic To Increase Spain's COVID-19 Testing Capacity

* ANNOUNCES COLLABORATION WITH HOLOGIC INC TO INCREASE THE COUNTRY’S TESTING CAPACITY FOR COVID-19

BRIEF-Hologic Sees Q3 Diagnostics Revenue To Grow 20-25%

* HOLOGIC INC SEES Q3 BREAST AND SKELETAL HEALTH REVENUE TO DECLINE 30-35%.

Hologic's latest COVID-19 test gets FDA approval for emergency use

Hologic Inc said on Friday the U.S. Food and Drug Administration granted emergency use authorization for its COVID-19 diagnostic test that can provide initial results in about three hours and process more than 1,000 tests in 24 hours.

BRIEF-Hologic Granted FDA Emergency Use Authorization For Its Second Molecular Test For Covid-19

* HOLOGIC GRANTED FDA EMERGENCY USE AUTHORIZATION FOR ITS SECOND MOLECULAR TEST FOR COVID-19

BRIEF-Hologic To Introduce Second High-Throughput Molecular Assay For Novel Coronavirus

* HOLOGIC TO INTRODUCE ITS SECOND HIGH-THROUGHPUT MOLECULAR ASSAY FOR THE NOVEL CORONAVIRUS (SARS-COV-2)

Hologic launches second COVID-19 test to help reach more Americans

Hologic Inc on Wednesday said it is launching a second COVID-19 test that will help to dramatically expand testing capabilities in the United States.

BRIEF-Hologic Reports Financial Results For Q2 2020

* HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL 2020

BRIEF-Hologic Withdraws 2020 Financial Guidance Due To Covid-19 Pandemic

* HOLOGIC ANNOUNCES PRELIMINARY REVENUE RESULTS FOR SECOND QUARTER OF FISCAL 2020, WITHDRAWS 2020 FINANCIAL GUIDANCE DUE TO COVID-19 PANDEMIC

BRIEF-Hologic - U.S. FDA-Issuing Emergency Use Authorizations To Hologic For Its Panther Fusion Sars-Cov-2 Assay

* U.S. FDA-ISSUING EMERGENCY USE AUTHORIZATIONS TO HOLOGIC FOR ITS PANTHER FUSION SARS-COV-2 ASSAY

BRIEF-Hologic's Molecular Test For The Novel Coronavirus, Sars-Cov-2, Receives FDA Emergency Use Authorization

* HOLOGIC’S MOLECULAR TEST FOR THE NOVEL CORONAVIRUS, SARS-COV-2, RECEIVES FDA EMERGENCY USE AUTHORIZATION

Hologic gets U.S. funding for coronavirus test kit

The U.S. Department of Health and Human Services said on Monday it will provide financial aid to Hologic Inc to develop a coronavirus diagnostic kit that would be able to process up to 1,000 tests in 24 hours.

BRIEF-HHS Supports Development Of First High-Throughput Covid-19 Diagnostic Test

* HHS Supports Development Of First High-Throughput Covid-19 Diagnostic Test

Hologic gets U.S. funding for coronavirus test kit

The U.S. Department of Health and Human Services said on Monday it would contribute $699,000 to speed up Hologic Inc's development of a coronavirus diagnostic test.

Hologic gets defense verdict in $90 million DNA testing patent case

Hologic Inc, its partner Grifols SA, and their lawyers at Arnold & Porter Kaye Scholer on Tuesday secured a defense verdict in a patent infringement case brought by rival medical diagnostics company bioMérieux SA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up